All In Biotech

Drug Trial Radar · NCT07677384

A Study to Evaluate the Safety of HS-10506 in Chinese Patients With Insomnia Disorder

A Multicenter, Open-label, Phase 3 Study to Evaluate the Short-term and Long-term Safety of HS-10506 in Chinese Adult Patients With Insomnia Disorder

Last checked: Nov 19, 2026Latest source record: Jun 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

600

Planned (sponsor's estimate)

Start

Jun 12, 2026

Primary completion

Jun 30, 2029

Study completion Jun 30, 2029

Sponsor

Sponsor type
Industry
First posted
Jun 30, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 64 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this open-label phase Ⅲ study is to evaluate the safety of HS-10506 on the incidence and severity of adverse events (AE), serious adverse events (SAE), adverse events of special interest (AESI) in Chinese adult participants with insomnia disorder.

Conditions

  • Insomnia Disorder

Interventions

  • HS-10506Drug

    HS-10506 tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and severity of adverse events (AE)Time frame: From date of signing the informed consent until the date of the end-of-study visit or early withdrawal, assessed up to 13 months
  2. Incidence and severity of serious adverse events (SAE)Time frame: From date of signing the informed consent until the date of the end-of-study visit or early withdrawal, assessed up to 13 months
  3. Incidence and severity of adverse events of special interest (AESI)Time frame: From date of signing the informed consent until the date of the end-of-study visit or early withdrawal, assessed up to 13 months

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.